# Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

> **NCT01120275** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Acral Lentiginous Malignant Melanoma
- Lentigo Maligna Malignant Melanoma
- Nodular Malignant Melanoma
- Recurrent Melanoma
- Solar Radiation-related Skin Melanoma
- Stage IV Melanoma
- Superficial Spreading Malignant Melanoma

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01120275
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2013-05
- **Final completion:** 2015-08
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01120275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01120275, "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT01120275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*